85710:BORRELIA BURGDORFERI IgG and IgM ANTIBODIES
Author PeaceHealth Laboratories
 Print View Attached Docs: |
| Alias Names: |
B. Burgdorferi / Lyme Disease |
| Methodology: |
Enzyme Immunoassay (EIA) |
| Edit Date: |
12/29/2010 |
| Performed: |
Tuesday-Saturday |
| Released: |
24 hours after setup at PeaceHealth Laboratories’ reference lab. |
| CPT Code: |
86618-90 x2 |
| Specimen Collection Details |
| Collection: |
One 7.5 mL serum separator tube (SST). |
| Handling: |
Allow to clot, centrifuge and separate serum into a plastic vial. Refrigerate. |
| Stability: |
7 days ambient, 14 days refrigerated, or 2 months frozen. |
| Standard Volume: |
2 mL serum. |
| Minimum Volume: |
0.5 mL serum. |
| Transport: |
Refrigerated. |
| Comments: |
Paired testing of acute and convalescent specimens is recommended. A Rapid Plasma Reagin (RPR) is performed at no charge on all specimens positive for Borrelia burgdorferi antibodies by enzyme immunoassay to exclude potential cross-reactions with syphilis. |
|
|
<.80 Index |
|
|
|
|
| Whole-cell sonicate (WCS) Borrelia burgdorferi antigens are utilized to measure both IgM and IgG antibody responses to B. burgdorferi in human serum, using an enzyme-immunoassay methodology (EIA). This test is used as a screen in a two-tier test algorithm proposed by the CDC for assessment of exposure to B. burgdorferi during early- and late-stage disease. For determination of early-stage Lyme disease (within the first 4 weeks of onset of erythema migrans), both IgM and IgG antibody detection should be evaluated. For late-stage Lyme disease (after 4 weeks of onset of erythema migrans), only IgG antibody detection should be evaluated. All IgM and IgG EIA positive results should be confirmed using the second tier immunoblot (IB) method.
|